Melissa Sanders, DO
Family Medicine · Pearl, MSNPI 1184156804
Payments from drug & device makers
Across 188 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$447
- Lilly USA, LLC$362
- AstraZeneca$241
- Exact Sciences$141
- Boehringer Ingelheim$101
- plus $750 from 21 others
What the payments were for
- Food & beverage$3,240100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 70 | $1,198 |
| Novo Nordisk | 27 | $447 |
| Lilly USA, LLC | 21 | $362 |
| AstraZeneca | 14 | $241 |
| Exact Sciences | 8 | $141 |
| Boehringer Ingelheim | 7 | $101 |
| Pfizer | 5 | $87 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $75 |
| GSK | 4 | $74 |
| Merck | 3 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $58 |
| Corcept Therapeutics | 3 | $57 |
| Currax Pharmaceuticals LLC | 3 | $50 |
| Biohaven Pharmaceuticals, Inc. | 3 | $42 |
| Eisai Inc. | 2 | $33 |
| Sanofi | 1 | $33 |
| Abbott | 1 | $25 |
| Inari Medical, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Medtronic | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Amgen | 1 | $16 |
| Viiv Healthcare Company | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Dexcom, Inc. | 1 | $11 |
How this compares
$3,240 in reported general payments places this provider in the 75th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 66 | $122,347 |
| OzempicSemaglutide | 67 | $110,639 |
| EliquisApixaban | 110 | $86,778 |
| JardianceEmpagliflozin | 41 | $68,345 |
| LinzessLinaclotide | 38 | $34,056 |
| JanuviaSitagliptin Phosphate | 28 | $31,592 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $23,295 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $22,028 |
| FarxigaDapagliflozin Propanediol | 16 | $21,584 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $18,271 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $16,984 |
| MyrbetriqMirabegron | 18 | $15,153 |
| Bydureon BciseExenatide Microspheres | 14 | $13,432 |
| EntrestoSacubitril/Valsartan | 15 | $13,117 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $12,450 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $362 | $122,34766 claims |
| Novo NordiskOzempic | $447 | $110,63967 claims |
| PfizerEliquis | $87 | $86,778110 claims |
| Boehringer IngelheimJardiance | $101 | $68,34541 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $241 | $51,01757 claims |
| MerckJanuvia, Belsomra | $60 | $36,60740 claims |
| AbbVieLinzess | $1,198 | $34,05638 claims |
| GSKTrelegy Ellipta | $74 | $23,29523 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $15,15318 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $18 | $4,78211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Pearl
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Rambod RouhbakhshHattiesburg$6M
- Randall HulingOlive Branch$4.6M
- Demetri MarshallPort Gibson$3M
- Alexander OsowaJackson$2.2M
- Russell CarlisleWesson$1.6M
- Kristi TrimmRidgeland$1.2M
- Keith StokesLexington$660K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.